Creatine Supplementation in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author ALVES, Christiano R. R.
SANTIAGO, Bianca M.
LIMA, Fernanda R. FMUSP-HC
OTADUY, Maria C. G. FMUSP-HC
CALICH, Ana Luisa FMUSP-HC
TRITTO, Aline C. C.
PINTO, Ana Lucia de Sa FMUSP-HC
ROSCHEL, Hamilton
LEITE, Claudia C. FMUSP-HC
BENATTI, Fabiana B. FMUSP-HC
BONFA, Eloisa FMUSP-HC
GUALANO, Bruno
dc.date.issued 2013
dc.identifier.citation ARTHRITIS CARE & RESEARCH, v.65, n.9, p.1449-1459, 2013
dc.identifier.issn 2151-464X
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/4010
dc.description.abstract Objective. To investigate the efficacy and safety of creatine supplementation in fibromyalgia patients. Methods. A 16-week, randomized, double-blind, placebo-controlled, parallel-group trial was conducted. Fibromyalgia patients were randomly assigned to receive either creatine monohydrate or placebo in a double-blind manner. The patients were evaluated at baseline and after 16 weeks. Muscle function, aerobic conditioning, cognitive function, quality of sleep, quality of life, kidney function, and adverse events were assessed. Muscle phosphorylcreatine content was measured through P-31 magnetic resonance spectroscopy. Results. After the intervention, the creatine group presented higher muscle phosphorylcreatine content when compared with the placebo group (+80.3% versus -2.7%; P = 0.04). Furthermore, the creatine group presented greater muscle strength than the placebo group in the leg press and chest press exercises (+9.8% and +1.2% for creatine versus -0.5% and -7.2% for placebo, respectively; P = 0.02 and P = 0.002, respectively). Isometric strength was greater in the creatine group than in the placebo group (+6.4% versus -3.2%; P = 0.007). However, no general changes were observed in aerobic conditioning, pain, cognitive function, quality of sleep, and quality of life. Food intake remained unaltered and no side effects were reported. Conclusion. Creatine supplementation increased intramuscular phosphorylcreatine content and improved lower- and upper-body muscle function, with minor changes in other fibromyalgia features. These findings introduce creatine supplementation as a useful dietary intervention to improve muscle function in fibromyalgia patients.
dc.description.sponsorship · CNPq
· FAPESP [2011/08302-0]
dc.language.iso eng
dc.publisher WILEY-BLACKWELL
dc.relation.ispartof Arthritis Care & Research
dc.rights restrictedAccess
dc.subject.other cognitive function; clinical-trial; renal-function; human brain; monohydrate; performance; disorder; tests; women; questionnaire
dc.title Creatine Supplementation in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial
dc.type article
dc.rights.holder Copyright WILEY-BLACKWELL
dc.description.group LIM/44
dc.description.group LIM/17
dc.identifier.doi 10.1002/acr.22020
dc.identifier.pmid 23554283
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author LIMA, Fernanda R.:FM:
hcfmusp.author OTADUY, Maria C. G.:HC:INRAD
hcfmusp.author CALICH, Ana Luisa:FM:
hcfmusp.author PINTO, Ana Lucia de Sa:HC:ICHC
hcfmusp.author LEITE, Claudia C.:FM:MDR
hcfmusp.author BENATTI, Fabiana B.:FM:
hcfmusp.author BONFA, Eloisa:FM:MCM
hcfmusp.author.external · ALVES, Christiano R. R.:Univ Sao Paulo, Sao Paulo, Brazil
· SANTIAGO, Bianca M.:Univ Sao Paulo, Sao Paulo, Brazil
· TRITTO, Aline C. C.:Univ Sao Paulo, Sao Paulo, Brazil
· ROSCHEL, Hamilton:Univ Sao Paulo, Sao Paulo, Brazil
· GUALANO, Bruno:Univ Sao Paulo, Sao Paulo, Brazil
hcfmusp.origem.id WOS:000323480600008
hcfmusp.origem.id 2-s2.0-84883314419
hcfmusp.publisher.city HOBOKEN
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Amital D, 2006, J PSYCHOSOM RES, V61, P663, DOI 10.1016/j.jpsychores.2006.07.003
· Andres RH, 2008, BRAIN RES BULL, V76, P329, DOI 10.1016/j.brainresbull.2008.02.035
· Antolic A, 2007, MED SCI SPORT EXER, V39, P816, DOI 10.1249/mss.0b013e318031fac4
· Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518
· Bennett R, 1996, J MUSCULOSKELET PAIN, V4, P35, DOI 10.1300/J094v04n01_05
· Brown LE, 2001, J EXERCISE PHYSL, V4, P21
· BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728
· Cohen J., 1988, STAT POWER ANAL BEHA
· Coplan JD, 2006, PSYCHIAT RES-NEUROIM, V147, P27, DOI 10.1016/j.pscychresns.2005.12.011
· CRONHOLM B, 1956, Nord Med, V56, P1612
· Dechent P, 1999, AM J PHYSIOL-REG I, V277, pR698
· Dechent P, 1999, BIOL PSYCHIAT, V46, P406, DOI 10.1016/S0006-3223(98)00346-1
· FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
· Gotshalk LA, 2008, EUR J APPL PHYSIOL, V102, P223, DOI 10.1007/s00421-007-0580-y
· Gualano B, 2008, EUR J APPL PHYSIOL, V103, P33, DOI 10.1007/s00421-007-0669-3
· Gualano B, 2011, AMINO ACIDS, V43, P519
· Gualano B, 2008, AMINO ACIDS, V34, P245, DOI 10.1007/s00726-007-0508-1
· Gualano B, 2011, EUR J APPL PHYSIOL, V111, P749, DOI 10.1007/s00421-010-1676-3
· Gualano B, 2011, MED SCI SPORT EXER, V43, P770, DOI 10.1249/MSS.0b013e3181fcee7d
· Hauser W, 2010, EUR J PAIN, V14, P5, DOI 10.1016/j.ejpain.2009.01.006
· Leader A, 2009, ANN NY ACAD SCI, V1173, P829, DOI 10.1111/j.1749-6632.2009.04811.x
· MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006
· McMorris T, 2007, PHYSIOL BEHAV, V90, P21, DOI 10.1016/j.physbeh.2006.08.024
· McMorris T, 2007, AGING NEUROPSYCHOL C, V14, P517, DOI 10.1080/13825580600788100
· Mease P, 2007, J RHEUMATOL, V34, P1415
· Mease PL, 2009, RHEUM DIS CLIN N AM, V35, P359, DOI 10.1016/j.rdc.2009.06.007
· MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8
· Neves M, 2011, MED SCI SPORT EXER, V43, P1538, DOI 10.1249/MSS.0b013e3182118592
· Neves M, 2011, APPL PHYSIOL NUTR ME, V36, P419, DOI [10.1139/h11-014, 10.1139/H11-014]
· Ravina B, 2006, NEUROLOGY, V66, P664
· Nitrini R, 2004, J INT NEUROPSYCH SOC, V10, P634, DOI 10.1017/S1355617704104062
· Park DC, 2001, ARTHRITIS RHEUM, V44, P2125, DOI 10.1002/1529-0131(200109)44:9<2125::AID-ART365>3.0.CO;2-1
· Park JH, 1998, ARTHRITIS RHEUM, V41, P406, DOI 10.1002/1529-0131(199803)41:3<406::AID-ART5>3.0.CO;2-L
· Poortmans JR, 2005, MED SCI SPORT EXER, V37, P1717, DOI 10.1294/01.mss.0000176398.64189.e6
· Poortmans JR, 1999, MED SCI SPORT EXER, V31, P1108, DOI 10.1097/00005768-199908000-00005
· Rae C, 2003, P ROY SOC B-BIOL SCI, V270, P2147, DOI 10.1098/rspb.2003.2492
· Rawson ES, 2008, PHYSIOL BEHAV, V95, P130, DOI 10.1016/j.physbeh.2008.05.009
· Rawson ES, 2011, AMINO ACIDS, V40, P1349, DOI 10.1007/s00726-011-0855-9
· Roschel H, 2011, PHYSIOTHERAPY, V97, P350, DOI 10.1016/j.physio.2011.01.007
· Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313
· Stockler S, 1996, LANCET, V348, P789, DOI 10.1016/S0140-6736(96)04116-5
· Tarnopolsky M, 1999, NEUROLOGY, V52, P854
· Watanabe A, 2002, NEUROSCI RES, V42, P279, DOI 10.1016/S0168-0102(02)00007-X
· WEBB WB, 1976, PERCEPT MOTOR SKILL, V43, P987
· WOLFE F, 1990, ARTHRITIS RHEUM, V33, P160, DOI 10.1002/art.1780330203
· WOLFE F, 1995, ARTHRITIS RHEUM, V38, P19, DOI 10.1002/art.1780380104
· Wolfe F, 1996, RHEUM DIS CLIN N AM, V22, P369, DOI 10.1016/S0889-857X(05)70277-5
· Wyss M, 2000, PHYSIOL REV, V80, P1107
dc.description.index MEDLINE
hcfmusp.citation.scopus 20
hcfmusp.citation.wos 16
hcfmusp.affiliation.country Brasil


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics